Filtered By:
Therapy: Cancer Therapy
Vaccination: Vaccines
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 377 results found since Jan 2013.
COVID-19 Outcomes, Patient Vaccination Status, and Cancer-Related Delays during the Omicron Wave: A Brief Report from the TERAVOLT Analysis
CONCLUSIONS: TERAVOLT found reduced patient mortality with the most recent COVID surge. COVID vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality.PMID:35619644 | PMC:PMC9119707 | DOI:10.1016/j.jtocrr.2022.100335
Source: Cell Research - May 27, 2022 Category: Cytology Authors: Christine M Bestvina Jennifer G Whisenant Valter Torri Alessio Cortellini Heather Wakelee Solange Peters Elisa Roca Alessandro De Toma Fred R Hirsch Hirva Mamdani Balazs Halmos Oscar Arrieta Anne-Cecile Metivier Mary J Fidler Jacobo Rogado Carolyn J Presl Source Type: research
Oncolytic virus delivery modulated immune responses toward cancer therapy: Challenges and perspectives
Int Immunopharmacol. 2022 May 24;108:108882. doi: 10.1016/j.intimp.2022.108882. Online ahead of print.ABSTRACTOncolytic viruses (OVs) harness the hallmarks of tumor cells and cancer-related immune responses for the lysis of malignant cells, modulation of the tumor microenvironment, and exertion of vaccine-like activities. However, efficient clinical exploitation of these potent therapeutic modules requires their systematic administration, especially against metastatic and solid tumors. Therefore, developing methods for shielding a virus from the neutralizing environment of the bloodstream while departing toward tumor sites...
Source: International Immunopharmacology - May 27, 2022 Category: Allergy & Immunology Authors: Mohsen Keshavarz Seyed Mohammad Miri Emad Behboudi Yaser Arjeini Hassan Dianat-Moghadam Amir Ghaemi Source Type: research
COVID-19 Outcomes, Patient Vaccination Status, and Cancer-Related Delays during the Omicron Wave: A Brief Report from the TERAVOLT Analysis
CONCLUSIONS: TERAVOLT found reduced patient mortality with the most recent COVID surge. COVID vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality.PMID:35619644 | PMC:PMC9119707 | DOI:10.1016/j.jtocrr.2022.100335
Source: Clinical Lung Cancer - May 27, 2022 Category: Cancer & Oncology Authors: Christine M Bestvina Jennifer G Whisenant Valter Torri Alessio Cortellini Heather Wakelee Solange Peters Elisa Roca Alessandro De Toma Fred R Hirsch Hirva Mamdani Balazs Halmos Oscar Arrieta Anne-Cecile Metivier Mary J Fidler Jacobo Rogado Carolyn J Presl Source Type: research
Oncolytic virus delivery modulated immune responses toward cancer therapy: Challenges and perspectives
Int Immunopharmacol. 2022 May 24;108:108882. doi: 10.1016/j.intimp.2022.108882. Online ahead of print.ABSTRACTOncolytic viruses (OVs) harness the hallmarks of tumor cells and cancer-related immune responses for the lysis of malignant cells, modulation of the tumor microenvironment, and exertion of vaccine-like activities. However, efficient clinical exploitation of these potent therapeutic modules requires their systematic administration, especially against metastatic and solid tumors. Therefore, developing methods for shielding a virus from the neutralizing environment of the bloodstream while departing toward tumor sites...
Source: International Immunopharmacology - May 27, 2022 Category: Allergy & Immunology Authors: Mohsen Keshavarz Seyed Mohammad Miri Emad Behboudi Yaser Arjeini Hassan Dianat-Moghadam Amir Ghaemi Source Type: research
Study on biomimetic nano tumor targeted delivery system for chemotherapy-laser immunotherapy
Eur J Pharm Biopharm. 2022 May 4:S0939-6411(22)00076-5. doi: 10.1016/j.ejpb.2022.04.004. Online ahead of print.ABSTRACTTo explore the immune adjuvant effect of nano mesoporous materials and laser immune effect of cancer therapy combined with chemotherapy, we designed a bionic nano tumor targeting delivery system with homologous cancer cell membrane as the outermost layer. Inorganic mesoporous silica (mSiO2) and hydroxyapatite (HAP) are used as the intermediate immune adjuvant layer and drug carrier layer, and gold nanorods(GNR) are used as the core. It degrade to release drug under the condition of low pH value, and the go...
Source: European Journal of Pharmaceutics and Biopharmaceutics - May 7, 2022 Category: Drugs & Pharmacology Authors: Yang Liu Tong Wang Yachao Ren Shuli Li Ijun Fu Jun Shi Source Type: research
Current and future direction in treatment of HPV-related cervical disease
J Mol Med (Berl). 2022 Apr 27. doi: 10.1007/s00109-022-02199-y. Online ahead of print.ABSTRACTHuman papillomavirus (HPV) is the most common sexually transmitted virus in the world. About 70% of cervical cancers are caused by the most oncogenic HPV genotypes of 16 and 18. Since available prophylactic vaccines do not induce immunity in those with established HPV infections, the development of therapeutic HPV vaccines using E6 and E7 oncogenes, or both as the target antigens remains essential. Also, knocking out the E6 and E7 oncogenes in host genome by genome-editing CRISPR/Cas system can result in tumor growth suppression. ...
Source: Molecular Medicine - April 28, 2022 Category: Molecular Biology Authors: Niloofar Khairkhah Azam Bolhassani Reza Najafipour Source Type: research
Optimization of large-scale manufacturing of biopolymeric and lipid nanoparticles using microfluidic swirl mixers
In this study, we present a novel microfluidic design (swirl mixer) that helps accelerating the translation of many DDSs from laboratory to clinical application. The new swirl mixer provides high production rate, reproducibility, and precise control of particle size with low polydispersity index (PDI). To assess the performance of the swirl mixer, two different types of nanoformulations were used: silk nanoparticles (SNPs) and lipid nanoparticles (LNPs). The microfluidic device produced NPs efficiently with high productivity and allow for tuning the mean size and size distribution by changing multiple processing parameters...
Source: Cancer Control - April 26, 2022 Category: Cancer & Oncology Authors: Mhd Anas Tomeh Muhamad Hawari Mansor Roja Hadianamrei Weizhen Sun Xiubo Zhao Source Type: research
An approach to p32/gC1qR/HABP1: a multifunctional protein with an essential role in cancer
J Cancer Res Clin Oncol. 2022 Apr 20. doi: 10.1007/s00432-022-04001-5. Online ahead of print.ABSTRACTP32/gC1qR/HABP1 is a doughnut-shaped acidic protein, highly conserved in eukaryote evolution and ubiquitous in the organism. Although its canonical subcellular localization is the mitochondria, p32 can also be found in the cytosol, nucleus, cytoplasmic membrane, and it can be secreted. Therefore, it is considered a multicompartmental protein. P32 can interact with many physiologically divergent ligands in each subcellular location and modulate their functions. The main ligands are C1q, hyaluronic acid, calreticulin, CD44, i...
Source: Cell Research - April 20, 2022 Category: Cytology Authors: Carlos Alejandro Egusquiza-Alvarez Martha Robles-Flores Source Type: research
Advances in Nanoparticle mediated Targeting of RNA Binding Protein for Cancer
Adv Drug Deliv Rev. 2022 Apr 2:114257. doi: 10.1016/j.addr.2022.114257. Online ahead of print.ABSTRACTRNA binding proteins (RBPs) enact a very crucial part in the RNA directive processes. Atypical expression of these RBPs affects many steps of RNA metabolism, majorly altering its expression. Altered expression and dysfunction of RNA binding proteins lead to cancer progression and other diseases. We enumerate various available interventions, and recent findings focused on targeting RBPs for cancer therapy and diagnosis. The treatment, sensitization, chemoprevention, gene-mediated, and virus mediated interventions were studi...
Source: Advanced Drug Delivery Reviews - April 5, 2022 Category: Drugs & Pharmacology Authors: Rama Kashikar Arun K Kotha Saurabh Shah Paras Famta Shashi Bala Singh Saurabh Srivastava Mahavir Bhupal Chougule Source Type: research
